Combating Cancer

Barron, Rachel
April 2007
Red Herring;4/16/2007, Vol. 4 Issue 14, p34
Trade Publication
The article offers information on the efforts of various companies to develop cancer drugs. According to research firm Kalorama Information, more than $11bn worth of new treatments are forecasted to gain approval from the U.S. Food and Drug Administration in the next four years. According to the World Health Organization, the disease claimed 7.6 million lives in 2005, and it is expected to kill 9 million in 2015. However, according to the author, those numbers could be curbed should pharmaceutical and biotechnology companies develop better cancer-fighting therapies.


Related Articles

  • DRUGS & MONEY. Novarro, Leonard // H&HN: Hospitals & Health Networks;08/05/97, Vol. 71 Issue 15, p54 

    Discusses the financial data of pharmaceutical companies in pouring unprecedented sums in research and development without guarantee that their drug will pass the Food and Drug Administration (FDA) scrutiny. Information about Remune, a human immunodeficiency virus (HIV) vaccine of Immune...

  • WALL STREET CHOICE: FDA ADVISORY COMMITTEE SURPRISINGLY PRO-PRASUGREL.  // Medical Marketing & Media;Mar2009, Vol. 44 Issue 3, p14 

    The article reports on the overall assessment of the U.S. Food and Drug Administration's (FDA) advisory committee of prasugrel in terms of its risk and benefit. It indicated that overall assessment was favorable, with few suggested limitations or precautions for usage. However, the committee did...

  • Biotech Review.  // CenterWatch Weekly;10/6/2014, Vol. 18 Issue 39, p12 

    The article offers information related to biotechnology industry. Topics discussed include the order from European Medicines Agency (EMA) head Guido Rasi to review Ebola treatments being developed, strategy of drugmakers to get innovative drugs on the Chinese market, and comment period for...

  • New law broadens FDA safety authority, renews user fees. Fox, Jeffrey L. // Nature Biotechnology;Nov2007, Vol. 25 Issue 11, p1189 

    The article reports on the new law which U.S. President George W. Bush had just signed on September 27, 2007 which is called the Prescription Drug User Fee Act in the U.S. Workers at the U.S. Food and Drug Administration (FDA) had been relieved after it became a law finally and so with the...

  • Hardly a wonder drug. Westphal, Sylvia Pag├ín // New Scientist;5/24/2003, Vol. 178 Issue 2396, p12 

    There's little evidence that the anti-cancer drug Iressa works, and there are evidences that it can trigger a deadly side effect. The drug was approved by the U.S. FDA on impetus given by Melissa Mahoney, who claims that the drug had led her to recovery from lung cancer. The drug was approved...

  • Other News To Note.  // BioWorld Today;8/12/2011, Vol. 22 Issue 156, p4 

    The article presents updates on the biotechnology industry including an investigational new drug (IND) application meeting held by Advaxis Inc. with the U.S. Food and Drug Administration (FDA), and the characterization of the anti-Prp antibodies in cellular assay systems of Amorfix Life Sciences...

  • WEEK IN WASHINGTON.  // BioWorld Insight;4/18/2011, Vol. 19 Issue 16, p6 

    The article offers updates in the biotechnology and pharmaceutical industry in Washington including the delay of the end-of-review meeting with MannKind Corp. by U.S. Food and Drug Administration and the approval of the Oncology Drugs and Advisory Committee on Novartis AG's Afinitor (everolimus)...

  • Congressional reform of FDA gets more suggestions from industry.  // Drug Topics;3/20/95, Vol. 139 Issue 6, p74 

    Reports on the assistance being given by three former Food and Drug Administration (FDA) commissioners and an former congressman to the pharmaceutical industry in devising an FDA reform plan to present to Congress. Biotechnology Industry Organization's announcement of its preliminary views on...

  • AVANIR INITIATES PHASE III CLINICAL TRIAL OF NEURODEX.  // Biotech Business;Aug2005, Vol. 18 Issue 8, p5 

    Reports on a clinical trial initiated by pharmaceutical firm Avanir Pharmaceuticals for the drug Neurodex in patients with diabetic neuropathic pain in 2005. Process used by the U.S. Food and Drug Administration to review the clinical trial protocol; Results of the previous trial; Background on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics